CD36 and atherosclerosis. Curr Opin Lipidol 2000 Oct;11(5):483-91
Date
10/26/2000Pubmed ID
11048891DOI
10.1097/00041433-200010000-00006Scopus ID
2-s2.0-0033775657 (requires institutional sign-in at Scopus site) 113 CitationsAbstract
CD36 has been associated with diverse normal and pathologic processes. These include scavenger receptor functions (uptake of apoptotic cells and modified lipid), lipid metabolism and fatty acid transport, adhesion, angiogenesis, modulation of inflammation, transforming growth factor-beta activation, atherosclerosis, diabetes and cardiomyopathy. Although CD36 was identified more than 25 years ago, it is only with the advent of recent genetic technology that in-vivo evidence has emerged for its physiologic and pathologic relevance. As these in-vivo studies are expanded, we will gain further insight into the mechanism(s) by which CD36 transmits a cellular signal, and this will allow the design of specific therapeutics that impact on a particular function of CD36.
Author List
Silverstein RL, Febbraio MAuthor
Roy L. Silverstein MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsArteriosclerosis
CD36 Antigens
Cell Adhesion
Humans
Inflammation
Lipid Metabolism
Membrane Proteins
Neovascularization, Pathologic
Receptors, Immunologic
Receptors, Lipoprotein
Receptors, Scavenger
Scavenger Receptors, Class B
Signal Transduction
Transforming Growth Factor beta
